-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $49

Benzinga·04/27/2026 10:01:26
Listen to the news
Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $48 to $49.